BlackRock
PHAS

BlackRock’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

BlackRock’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-665,563
Closed -$116K – 5966
2022
Q3 		$116K Sell
665,563
-18,641
-3% -$19K ﹤0.01% 5135
2022
Q2 		$411K Buy
684,204
+2,713
+0.4% +$2.6K ﹤0.01% 4834
2022
Q1 		$899K Sell
681,491
-3,906
-0.6% -$6.33K ﹤0.01% 4701
2021
Q4 		$1.79M Buy
685,397
+166,038
+32% +$502K ﹤0.01% 4448
2021
Q3 		$1.61M Buy
519,359
+32,335
+7% +$108K ﹤0.01% 4404
2021
Q2 		$1.81M Sell
487,024
-732,101
-60% -$2.44M ﹤0.01% 4317
2021
Q1 		$4.22M Buy
1,219,125
+25,518
+2% +$104K ﹤0.01% 4014
2020
Q4 		$4.01M Buy
1,193,607
+58,668
+5% +$210K ﹤0.01% 3794
2020
Q3 		$3.98M Buy
1,134,939
+52,770
+5% +$213K ﹤0.01% 3664
2020
Q2 		$4.98M Buy
1,082,169
+92,379
+9% +$409K ﹤0.01% 3523
2020
Q1 		$3.28M Sell
989,790
-9,918
-1% -$45.4K ﹤0.01% 3497
2019
Q4 		$6.11M Buy
999,708
+79,666
+9% +$328K ﹤0.01% 3445
2019
Q3 		$3.83M Buy
920,042
+24,615
+3% +$196K ﹤0.01% 3559
2019
Q2 		$11.7M Buy
895,427
+850,166
+1,878% +$10.4M ﹤0.01% 3164
2019
Q1 		$430K Buy
45,261
+19,952
+79% +$79K ﹤0.01% 4120
2018
Q4 		$79K Buy
+25,309
New +$100K ﹤0.01% 4397

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

BlackRock's PHAS Position: Q4 2022 in Review

BlackRock sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 665,563 shares — an estimated $116K sold.

BlackRock first reported a position in PHAS in Q4 2018 and held it in 16 quarters. The position peaked at $11.7M in Q2 2019. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • BlackRock reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • BlackRock sold 665,563 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $116K.
  • BlackRock first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 16 quarters.
  • BlackRock's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $11.7M in Q2 2019.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.